alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
# C_2014292EN.01004602.xml

| 1.9.2014 | EN | Official Journal of the European Union | C 292/46 |
| --- | --- | --- | --- |

1.9.2014

EN

Official Journal of the European Union

C 292/46

---

Action brought on 6 June 2014 — Junited Autoglas Deutschland v OHIM — United Vehicles (UNITED VEHICLEs)

(Case T-404/14)

2014/C 292/57

Language in which the application was lodged: German

Parties

Parties

Applicant: Junited Autoglas Deutschland GmbH & Co. KG (Cologne, Germany) (represented by: C. Weil, lawyer)

Applicant:

Defendant: Office for Harmonisation in the Internal Market (Trade Marks and Designs)

Defendant:

Other party to the proceedings before the Board of Appeal: United Vehicles GmbH (Munich, Germany)

Other party to the proceedings before the Board of Appeal:

Form of order sought

Form of order sought

The applicant claims that the Court should:

| — | Annul the decision of the Fourth Board of Appeal of the Office for Harmonisation in the Internal Market (Trade Marks and Designs) of 7 April 2014 in Case R 859/2013-4; |
| --- | --- |

—

Annul the decision of the Fourth Board of Appeal of the Office for Harmonisation in the Internal Market (Trade Marks and Designs) of 7 April 2014 in Case R 859/2013-4;

| — | Uphold the appeal; |
| --- | --- |

—

Uphold the appeal;

| — | Uphold the opposition based on earlier Community trade mark No 6 0 25  399; |
| --- | --- |

—

Uphold the opposition based on earlier Community trade mark No 6 0 25  399;

| — | And dismiss the application for registration of the word mark ‘UNITED VEHICLES’; |
| --- | --- |

—

And dismiss the application for registration of the word mark ‘UNITED VEHICLES’;

| — | Order OHIM to pay the costs. |
| --- | --- |

—

Order OHIM to pay the costs.

Pleas in law and main arguments

Pleas in law and main arguments

Applicant for a Community trade mark: United Vehicles GmbH

Applicant for a Community trade mark:

Community trade mark concerned: the word mark ‘UNITED VEHICLEs’ for services in Classes 35, 36, 38 and 42 — Community trade mark application No 1 0 3 30  041

Community trade mark concerned:

Proprietor of the mark or sign cited in the opposition proceedings: the applicant

Proprietor of the mark or sign cited in the opposition proceedings:

Mark or sign cited in opposition: the word mark ‘Junited’ for goods and services in Classes 1, 3, 7, 8, 9, 12, 14, 16, 17, 19, 21, 25, 26, 35, 36, 37 and 39 to 41

Mark or sign cited in opposition:

Decision of the Opposition Division: the opposition was rejected

Decision of the Opposition Division:

Decision of the Board of Appeal: the appeal was dismissed

Decision of the Board of Appeal:

Pleas in law: Infringement of Article 8(1)(b) of Regulation No 207/2009

Pleas in law:

---
[Federal Register Volume 75, Number 43 (Friday, March 5, 2010)]
[Notices]
[Page 10295]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2010-4726]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


Center for Scientific Review; Notice of Closed Meetings

    Pursuant to section 10(d) of the Federal Advisory Committee Act, as 
amended (5 U.S.C. App.), notice is hereby given of the following 
meetings.
    The meetings will be closed to the public in accordance with the 
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 
U.S.C., as amended. The grant applications and the discussions could 
disclose confidential trade secrets or commercial property such as 
patentable material, and personal information concerning individuals 
associated with the grant applications, the disclosure of which would 
constitute a clearly unwarranted invasion of personal privacy.

    Name of Committee: Center for Scientific Review Special Emphasis 
Panel Member Conflict: Topics in Aging, Cellular and Developmental 
Biology.
    Date: March 23, 2010.
    Time: 1 p.m. to 3 p.m.
    Agenda: To review and evaluate grant applications.
    Place: National Institutes of Health, 6701 Rockledge Drive, 
Bethesda, MD 20892 (Telephone Conference Call).
    Contact Person: Sherry L. Dupere, PhD, Scientific Review 
Officer, Center for Scientific Review, National Institutes of 
Health, 6701 Rockledge Drive, Room 5136, MSC 7843, Bethesda, MD 
20892, (301) 435-1021, <a href="/cdn-cgi/l/email-protection#cda9b8bda8bfa8be8daebebfe3a3a4a5e3aaa2bb"><span class="__cf_email__" data-cfemail="1a7e6f6a7f687f695a79696834747372347d756c">[email protected]</span></a>.

    Name of Committee: Center for Scientific Review Special Emphasis 
Panel Member Conflicts: Arthritis, Connective Tissue, and Skin.
    Date: March 30, 2010.
    Time: 1:30 p.m. to 4 p.m.
    Agenda: To review and evaluate grant applications.
    Place: National Institutes of Health, 6701 Rockledge Drive, 
Bethesda, MD 20892 (Telephone Conference Call).
    Contact Person: Jean D. Sipe, PhD., Scientific Review Officer, 
Center for Scientific Review, National Institutes of Health, 6701 
Rockledge Drive, Room 4106, MSC 7814, Bethesda, MD 20892, 301/435-
1743, <a href="/cdn-cgi/l/email-protection#44372d34212e042737366a2a2d2c6a232b32"><span class="__cf_email__" data-cfemail="c3b0aab3a6a983a0b0b1edadaaabeda4acb5">[email protected]</span></a>.

(Catalogue of Federal Domestic Assistance Program Nos. 93.306, 
Comparative Medicine; 93.333, Clinical Research, 93.306, 93.333, 
93.337, 93.393-93.396, 93.837-93.844, 93.846-93.878, 93.892, 93.893, 
National Institutes of Health, HHS)

    Dated: March 1, 2010.
Jennifer Spaeth,
Director, Office of Federal Advisory Committee Policy.
[FR Doc. 2010-4726 Filed 3-4-10; 8:45 am]
BILLING CODE 4140-01-P


</pre><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script></body>
</html>
<TABLE> <S> <C>

<ARTICLE> 5
<LEGEND>
THIS SCHEDULE CONTAINS SUMMARY FINANCIAL INFORMATION EXTRACTED FROM MOSAIX, INC.
AND IS QUALIFIED IN ITS ENTIRETY BY REFERENCE TO SUCH 10K.
</LEGEND>
<MULTIPLIER> 1,000
<CURRENCY> U.S. DOLLARS
       
<S>                             <C>                     <C>
<PERIOD-TYPE>                   3-MOS                   9-MOS
<FISCAL-YEAR-END>                          DEC-31-1998         DEC-31-1998
<PERIOD-START>                             JUL-01-1998         JAN-01-1998
<PERIOD-END>                               SEP-30-1998         SEP-30-1998
<EXCHANGE-RATE>                                      1                   1
<CASH>                                           9,328               9,328
<SECURITIES>                                    24,185              24,185
<RECEIVABLES>                                   29,992              29,992
<ALLOWANCES>                                     1,976               1,976
<INVENTORY>                                      1,164               1,164
<CURRENT-ASSETS>                                68,243              68,243
<PP&E>                                          28,556              28,556
<DEPRECIATION>                                  20,609              20,609
<TOTAL-ASSETS>                                  77,351              77,351
<CURRENT-LIABILITIES>                           27,098              27,098
<BONDS>                                              0                   0
<PREFERRED-MANDATORY>                                0                   0
<PREFERRED>                                          0                   0
<COMMON>                                           129                 129
<OTHER-SE>                                      50,124              50,124
<TOTAL-LIABILITY-AND-EQUITY>                    77,351              77,351
<SALES>                                         16,622              48,411
<TOTAL-REVENUES>                                27,099              81,573
<CGS>                                            5,358              14,970
<TOTAL-COSTS>                                   11,158              34,871
<OTHER-EXPENSES>                                14,455              45,817
<LOSS-PROVISION>                                    60                 202
<INTEREST-EXPENSE>                                (11)                  28
<INCOME-PRETAX>                                  1,934               2,289
<INCOME-TAX>                                       329                 435
<INCOME-CONTINUING>                                  0                   0
<DISCONTINUED>                                       0                   0
<EXTRAORDINARY>                                      0                   0
<CHANGES>                                            0                   0
<NET-INCOME>                                     1,605<F1>           1,854<F1>
<EPS-PRIMARY>                                     0.14                0.15
<EPS-DILUTED>                                     0.14                0.15
<FN>
<F1>For purposes of this exhibit, Primary means Basic.
</FN>
        

</TABLE>
QuickLinks
 -- Click here to rapidly navigate through this document

 
 

Exhibit 10.91    
  


 
 

EXTENSION AGREEMENT    
  


Bank
of America, N.A.,

    as Administrative Agent

Attn: Suzanne Paul

231 South LaSalle Street

Chicago, Illinois 60604 


Ladies
and Gentlemen: 


        The
undersigned hereby agrees to extend, effective April 3, 2002, its Commitment and the Maturity Date under the Credit Agreement dated as of April 3, 2001 among
SOURCECORP, Incorporated, f/k/a F.Y.I. Incorporated, each of the Lenders party thereto, Bank of America, N.A., as Administrative Agent, and Banc of America Securities LLC, as sole lead arranger and
sole book agent (as the same may be amended or otherwise modified from time to time, the "Credit Agreement") for 364 days to April 2, 2005
pursuant to Section 2.1(d) of the Credit Agreement. Terms defined in the Credit Agreement are used herein as therein defined. 


        This
Extension Agreement shall be construed in accordance with and governed by the law of the State of Texas. The Extension Agreement may be signed in any number of counterparts, each of
which shall be an original, with the same effect as if the signatures thereto and hereto were upon the same instrument. 



	

 	
 	
JPMorgan Chase Bank formerly known as

The Chase Manhattan Bank
	

 	
 	

Name:	

/s/ MICHAEL D.S. KERNER

	 	 	 	By:	Michael D.S. Kerner

	 	 	 	Title:	Vice President






	

Agreed and Accepted:
	

SOURCECORP, INCORPORATED, f/k/a

F.Y.I. INCORPORATED
	

By:	

/s/ BARRY EDWARDS

	Name:	Barry Edwards

	Title:	EVP & CFO

	

BANK OF AMERICA, N.A., as Administrative Agent
	

By:	

/s/ SUZANNE M. PAUL

	Name:	Suzanne M. Paul

	Title:	Vice President












QuickLinks



Exhibit 10.91


EXTENSION AGREEMENT
UNPUBLISHED UNITED STATES COURT OF APPEALS FOR THE FOURTH CIRCUIT No. 98-6098

UNITED STATES OF AMERICA, Plaintiff - Appellee, versus JOSE FERNANDO MERCEDES, Defendant - Appellant.Appeal from the United States District Court for the Eastern District of Virginia, at Alexandria. Claude M. Hilton, Chief District Judge. (CR-95-39, CA-97-1564-AM) Submitted: August 13, 1998 Decided: September 1, 1998 Before WIDENER and WILKINS, Circuit Judges, and HALL, Senior Circuit Judge. Dismissed by unpublished per curiam opinion. Jose Fernando Mercedes, Appellant Pro Se. Thomas More Hollenhorst, Assistant United States Attorney, Alexandria, Virginia, for Appellee. Unpublished opinions are not binding precedent in this circuit. See Local Rule 36(c).2 PER CURIAM: Jose Fernando Mercedes seeks to appeal the district court’s order denying his motion filed under 28 U.S.C.A.§ 2255 (West 1994 & Supp. 1998). We have reviewed the record and the district court’sopinion and find no reversible error. Accordingly, we deny a certificate of appealability and dismiss the appeal on the reasoning of the district court. United States v. Mercedes , No. CR-95-39 (E.D. Va. Jan. 15, 1998) We dispense with oral argument becausethe facts and legal contentions are adequately presented in the materials before the court and argument would not aid the decisional process.

DISMISSED
Editorial Note on Part 874
Editorial Note: Nomenclature changes to part 874 appear at 73 FR 35341, June 23, 2008.

§ 874.3340 Active implantable bone conduction hearing system. ( a ) *Identification.* An active implantable bone conduction hearing system is a prescription device consisting of an implanted transducer, implanted electronics components, and an audio processor. The active implantable bone conduction hearing system is intended to compensate for conductive or mixed hearing losses by conveying amplified acoustic signals to the cochlea via mechanical vibrations on the skull bone.
( b ) *Classification.* Class II (special controls). The special controls for this device are: ( 1 ) Clinical performance testing must characterize any adverse events observed during implantation and clinical use, and must also demonstrate that the device performs as intended under anticipated conditions of use.
( 2 ) Non-clinical performance testing must demonstrate that the device performs as intended under anticipated conditions of use, including the following: ( i ) Performance data must validate force output in a clinically relevant model.
( ii ) Impact testing in a clinically relevant anatomic model must be performed.
( iii ) Mechanical integrity testing must be performed.
( iv ) Reliability testing consistent with expected device life must be performed.
( 3 ) The patient-contacting components of the device must be demonstrated to be biocompatible.
( 4 ) Performance data must demonstrate the sterility of the patient-contacting components of the device.
( 5 ) Performance data must support the shelf life of the device by demonstrating continued sterility, package integrity, and device functionality over the identified shelf life.
( 6 ) Performance data must demonstrate the wireless compatibility, electromagnetic compatibility, and electrical safety of the device.
( 7 ) Software verification, validation, and hazard analysis must be performed.
( 8 ) Labeling must include: ( i ) A summary of clinical testing conducted with the device that includes a summary of device-related complications and adverse events;
( ii ) Instructions for use;
( iii ) A surgical guide for implantation, which includes instructions for imaging to assess bone dimensions;
( iv ) A shelf life, for device components provided sterile;
( v ) A patient identification card; and
( vi ) A patient user manual.
[83 FR 54009, Oct. 26, 2018]
<TABLE> <S> <C>

<ARTICLE> 5
<MULTIPLIER> 1,000
       
<S>                             <C>
<PERIOD-TYPE>                   6-MOS
<FISCAL-YEAR-END>                          JAN-31-1999
<PERIOD-START>                             MAY-01-1998
<PERIOD-END>                               OCT-31-1998
<CASH>                                         (1,330)
<SECURITIES>                                         0
<RECEIVABLES>                                      362
<ALLOWANCES>                                         0
<INVENTORY>                                     44,778
<CURRENT-ASSETS>                                47,566
<PP&E>                                          31,256
<DEPRECIATION>                                   1,291
<TOTAL-ASSETS>                                  83,439
<CURRENT-LIABILITIES>                           27,073
<BONDS>                                         40,211
<PREFERRED-MANDATORY>                            7,887
<PREFERRED>                                          0
<COMMON>                                         2,888
<OTHER-SE>                                       1,690
<TOTAL-LIABILITY-AND-EQUITY>                    83,439
<SALES>                                         75,201
<TOTAL-REVENUES>                                75,201
<CGS>                                           49,612
<TOTAL-COSTS>                                   49,612
<OTHER-EXPENSES>                                23,086
<LOSS-PROVISION>                                     0
<INTEREST-EXPENSE>                               1,885
<INCOME-PRETAX>                                    627
<INCOME-TAX>                                       251
<INCOME-CONTINUING>                                376
<DISCONTINUED>                                       0
<EXTRAORDINARY>                                      0
<CHANGES>                                            0
<NET-INCOME>                                       376
<EPS-PRIMARY>                                   (0.00)
<EPS-DILUTED>                                   (0.00)
        

</TABLE>
UNPUBLISHED UNITED STATES COURT OF APPEALS FOR THE FOURTH CIRCUIT No. 99-7686

IAN CARL ALLEN, Petitioner - Appellant, versus ROBERT SMITH, Respondent - Appellee.Appeal from the United States District Court for the Eastern District of North Carolina, at Raleigh. Terrence W. Boyle, Chief District Judge. (CA-99-341-5-BO) Submitted: March 23, 2000 Decided: March 30, 2000 Before LUTTIG, WILLIAMS, and MICHAEL, Circuit Judges. Dismissed by unpublished per curiam opinion. Ian Carl Allen, Appellant Pro Se. Clarence Joe DelForge, III, OFFICE OF THE ATTORNEY GENERAL OF NORTH CAROLINA, Raleigh, North Carolina, for Appellee. Unpublished opinions are not binding precedent in this circuit. See Local Rule 36(c).* Although the district court’s order is marked as “filed” on November 2, 1999, the district court’s records show that it was entered on the docket sheet on November 3, 1999. Pursuant to Rules 58 and 79(a) of the Federal Rules of Civil Procedure, it is the date the order was entered on the docket sheet that we take as the effective date of the district court’s decision. See Wilson v. Murray, 806 F.2d 1232, 1234-35 (4th Cir. 1986). 2 PER CURIAM: Ian Carl Allen appeals the district courts order denying relief on his petition filed under 28 U.S.C.A. § 2254 (West 1994 & Supp. 1999). We have reviewed the record and the district court'sopinion and find no reversible error. Accordingly, we deny a certificate of appealability and dismiss the appeal on the reasoning of the district court. See Allen v. Smith , No. CA-99-341-5-BO (E.D.N.C. Nov. 3, 1999). * We dispense with oral argument becausethe facts and legal contentions are adequately presented in the materials before the court and argument would not aid the decisional process.

DISMISSED
|   |  1. | The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and |
|--------|----------|---------------------------------------------------------------------------------------------------------------------------------|

|   |  2. | The information contained in the Report fairly presents, in all material respects, the financial condition and results of operation of the Company. |
|--------|----------|---------------------------------------------------------------------------------------------------------------------------------------------------------------|

| Date:  |  August 16, 2010 |   | By:    |  /s/ Edward P. Smolyansky                                                          |   |
|--------|-----------------------|--------|--------|-----------------------------------------------------------------------------------------|--------|
|   |                  |   |   | Edward P. SmolyanskyChief Financial and Accounting Officer and Treasurer |   |
#### Shehan *et al. v.*Hofmayer Dry Goods Company *et al.*

No. 9050.

June, 16, 1932.

Gilbert, J.

The evidence was insufficient to support the verdict, and the court erred in refusing to grant a new trial.

*Judgment reversed.*

*Russell, G. J., Beck, P. J., and Atkinson and Hill, JJ., concur.*

*909
      *B. I. Stephens*and *L. F. Watson,*for plaintiff in error.

*C. G. Crockett,*contra.
Kentucky Energy and Environment Cabinet

Kentucky Division for Air Quality



# -------------------------------------------

Appendix C.3 Secondary Organic Aerosol

Module Modifications in CMAQ[This page intentionally left blank.]
Editorial Note on Part 878
Editorial Note: Nomenclature changes to part 878 appear at 73 FR 35341, June 23, 2008.

§ 878.4454 Non-absorbable, hemostatic gauze for temporary internal use. ( a ) *Identification.* A non-absorbable, hemostatic gauze for temporary internal use is a prescription device intended to be placed temporarily for control of severely bleeding wounds such as surgical wounds and traumatic injuries. The gauze is coated or impregnated with a hemostatic material which may enhance hemostasis by physical means. The device is intended to be removed once the patient is stabilized.
( b ) *Classification.* Class II (special controls). The special controls for this device are: ( 1 ) Animal performance testing must demonstrate that the device performs as intended under anticipated conditions of use. Specifically testing must: ( i ) Demonstrate that the device is able to achieve hemostasis;
( ii ) Demonstrate that the device can be radiographically detected; and
( iii ) Assess pertinent safety endpoints including vascular obstruction and adhesion formation.
( 2 ) The device must be demonstrated to be biocompatible.
( 3 ) Non-clinical performance data must demonstrate that the device performs as intended under anticipated conditions of use. The following tests must be performed: ( i ) In vitro clot assessment;
( ii ) Particulate release testing;
( iii ) Physical characterization, including swelling percent and particulate size;
( iv ) Chemical characterization;
( v ) Radiopacity testing; and
( vi ) Mechanical integrity testing, including tensile strength and tear strength.
( 4 ) Performance data must demonstrate the sterility of the device.
( 5 ) Performance data must support the shelf life of the device by demonstrating continued sterility, package integrity, and device functionality over the identified shelf life.
( 6 ) Labeling must include the following: ( i ) Instructions for use, including an instruction to remove all visible device components by irrigation;
( ii ) The maximum amount of time the device may be left within the body;
( iii ) A shelf life;
( iv ) A contraindication for intravascular use of the device; and
( v ) A warning regarding the potential for adhesion formation.
[83 FR 6794, Feb. 15, 2018]